SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS (tradipitant), hailed as the first new motion sickness drug in over 40 years. The community is buzzing about its substantial potential to address GLP-1 induced nausea and vomiting, viewing this as a significant market expansion that could drive a revaluation of the company. With additional pipeline catalysts anticipated, many are expressing strong conviction in its future growth, despite some predicting immediate profit-taking.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amid intense community debate, largely driven by ongoing price depreciation attributed to tax loss harvesting and persistent selling pressure from SPAC-related share overhang. Despite recent inclusion in the Russell 2000/3000 indexes and reported strong revenue growth in its latest quarter, sentiment remains highly polarized. Bulls view the stock as deeply undervalued with significant long-term potential from user growth and international expansion, while bears warn of continued dilution and question the company's valuation.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid sharp investor division, primarily driven by the recent FDA approval of Novo Nordisk's oral Wegovy pill and speculation around potential distribution partnerships for GLP-1 treatments. While many note the stock's significant drawdown and high short interest as bearish indicators, others view the current valuation as a prime long-term buying opportunity, citing strong fundamentals, institutional accumulation, and the company's expansion into new health verticals and international markets. The community is actively debating whether the current dip sets the stage for a short squeeze or further decline for the direct-to-consumer telehealth provider.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is currently trending amidst significant investor frustration as its stock repeatedly hits new all-time lows, fueling widespread community debate over perceived management effectiveness and production execution. Despite recent accolades for its Gravity SUV and strategic partnerships, conversation is heavily focused on the extended interim CEO tenure, potential dilution, and critical concerns about meeting annual vehicle production targets compared to surging EV competitors.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively debated amid its significant price volatility, with many investors anticipating potential breakthroughs and new partnerships at the upcoming CES 2026. While some highlight its robust contractual backlog, growing revenues in voice AI, and debt-free status as a compelling buying opportunity, others express deep skepticism regarding management's communication and the stock's recent performance.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics Holdings is capturing market attention following a proposed business combination with Applied Digital, which would see Applied Digital's cloud GPU business spun off into ChronoScale, an AI compute platform. The potential "AI merger" is fueling fervent discussion among traders, with many anticipating a significant run due to the stock's low float, while others express concerns about potential shareholder dilution.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is at the center of investor attention with a highly anticipated regulatory decision for its Cushing's syndrome drug, relacorilant, prompting intense community debate and significant trading volume. Traders are closely watching for an approval or a potential Complete Response Letter, weighing recent sector approvals against CORT's price action and broader pipeline, including its ovarian cancer program, which fuels long-term bullish sentiment despite short-term uncertainty.

Themes ETF Trust - Leverage Shares 2X Long UNH Daily ETF

Leverage Shares 2X Long UNH Daily ETF

UNHG is trending amid widespread investor frustration over a significant price drop that appears decoupled from the performance of its underlying asset, UNH. The community is actively discussing a recent dividend event, which many perceive as fund manipulation or unusual decay rather than a true payout, raising serious concerns about the leveraged ETF's tracking accuracy. This has fueled a broader debate on the legitimacy and reliability of this relatively new 2x leveraged offering, with many advising caution against long-term positions.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is currently a hot topic among crypto communities, with many drawing parallels to early Pepe and some associating it with creator Matt Furie. Enthusiasts are actively accumulating due to its low market capitalization, anticipating significant price movements and aiming to 'drop a zero' in its value as part of a broader meme coin rally.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending with strong community conviction as it achieves new all-time highs and sees increased market activity, fueled by its growing presence on Ethereum. The community is actively discussing its sustained momentum, robust chart action, and a narrative positioning it as a significant player in the ongoing "ETH season" amidst broader market shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update

Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 650,544 shares, an...

Citius Oncology, Inc. Full Year Loss Increases

(RTTNews) - Citius Oncology, Inc. (CTOR) reported Loss for its full year of -$24.76 million...

Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results

Citius Oncology (NASDAQ:CTOR - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter...

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire...

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business...

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces Closing of $18 Million...

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces $18 Million Concurrent Registered...

Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East...

<ul class="summary-bullets"><li>FDA approved Lymphir for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma.</li><li>Phase 3 data showed a 36.2% response rate, with most patients seeing reduced skin tumor burden.</li><li>Lymphir is available nationwide with a permanent J-code effective April to support reimbursement.</li></ul>Citius Oncology (CTOR) said on Monday it has launched&nbsp;Lymphir, a newly approved cancer immunotherapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL), making the drug available nationwide through specialty distributors.The U.S. Food and Drug Administration (FDA) approved Lymphir, also known as denileukin diftitox-cxdlfor adults with cutaneous T-cell lymphoma, a form of skin cancer that can cause painful, itchy lesions. The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.The stock jumped nearly 18% to $1.62 at the time of writing.&nbsp;<h2 class="st-heading-2">Clinical Findings</h2>The immunotherapy approval was supported by results from Phase 3 Study 302, which reported an objective response rate of 36.2%. According to Citius, 84% of evaluable patients saw reductions in skin tumor burden, and the median time to response was 1.4 months. The company said the therapy was not associated with cumulative toxicity.Lymphir is the first FDA-approved systemic therapy for CTCL in more than seven years. It has been added to the National Comprehensive Cancer Network guidelines with a Category 2A recommendation, meaning the therapy is recommended, with uniform agreement from experts.&nbsp;<h2 class="st-heading-2">Commercial Rollout&nbsp;</h2>Lymphir has a permanent J-code, effective since April, to support reimbursement. Citius is providing medical education, payer-access support and a patient assistance program, which includes reimbursement and benefits guidance as well as prior authorization support.&nbsp;<h2 class="st-heading-2">Global Expansion Plans&nbsp;</h2>Outside the U.S., Citius holds rights to develop and commercialize Lymphir in all markets except India, Japan and certain parts of Asia. The company recently signed a distribution agreement with Integris Pharma to begin named-patient access programs in Greece, Cyprus and other Southern European and Balkan countries.<h2 class="st-heading-2">Stocktwits Users Turn ‘Extremely Bullish’</h2>On Stocktwits, retail sentiment for Citius Oncology turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:969/142;" src="https://news.stocktwits-cdn.com/ctor_ss_png_c597304fdc.webp" alt="ctor ss.png" width="969" height="142"><figcaption>CTOR sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure>One bullish user said, “interesting to see what happens here - back on the scanner!”<stembedurl>https://stocktwits.com/JammyGitTradaz/message/637812831</stembedurl>Another user suggested the stock could return to $5.&nbsp;<stembedurl>https://stocktwits.com/CookieWatcher/message/637811657</stembedurl><a href="https://stocktwits.com/symbol/CTOR">CTOR stock</a> rose nearly 43% so far this year.&nbsp;Get updates to this developing story directly on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Citius Oncology stock (CTOR) jumped nearly 14% at the time of writing.  (Photo credit: Getty Images)

Citius Oncology Launches Lymphir In US For Skin Cancer — Retail Traders Eye Major Upside

The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.

Equity

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel...

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

CTOR
Citius Oncology Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CTOR News

CTORCitius Oncology Inc.